

**Remarks**

Claims 18-24, 26, 40 and 41 are pending in this application. Without prejudice or disclaimer, and in consideration of the new U.S.P.T.O. Rules, 37 C.F.R. 1.75(b), Examination of Claims, Claims 1-17, 25, 27-30, 33-36, 38, 39 and 42 are cancelled in this paper. Claims 31, 32 and 37 were previously cancelled.

There is ample support in the specification (such as page 38, last 3 lines through page 42, line 10) for the claimed subject matter of Claim 18, in addition to the claim as originally filed.

Solely for the convenience of examination of the present application and to facilitate prosecution, Applicants provide the following information.

<b>Compound of Claim 18</b>	<b>Additional Support in Specification</b>
6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-nicotinamide	Example 271, page 159
5-{2-Fluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-pyrazine-2-carboxamide	Example 745, page 480
5-(2-Methoxy-4-pentylaminomethyl-phenoxy)-pyrazine-2-carboxamide	Example 719, page 456, last line through page 457, last line
6-(2-Fluoro-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-nicotinamide	Example 757, page 487, last five lines through page 488, line 7
6-(2,3-Difluoro-4-pentylaminomethyl-phenoxy)-nicotinamide	Example 710, page 444, last 4 lines through page 446, line 17
5-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)-pyrazine-2-carboxamide	Example 767, page 494, line 14 through page 495, line 5
5-{4-[(4,4-Dimethyl-pentylamino)-methyl]-2-methoxy-phenoxy}-pyrazine-2-carboxamide	Example 765, page 493, lines 1-18
5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide	Example 720, page 458, lines 1-15
5-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-fluoro-phenoxy}-pyrazine-2-carboxamide	Example 737, page 471, line 15 through page 475, line 4
5-(2-Fluoro-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-	Example 749, page 482, line 18 through page 483, line 9

carboxamide	
6-{2-Methyl-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide	Example 227, page 137, lines 2-14
5-(2-Methyl-4-[(2-(tetrahydro-pyran-4-yl)-ethylamino)-methyl]-phenoxy)-pyrazine-2-carboxamide	Example 435, page 282, lines 6 through the end of page
6-{4-[(3,3-Dimethyl-butylamino)-methyl]-2-fluoro-6-methoxy-phenoxy}-nicotinamide	Example 711, page 446, line 18 through page 447, line 19
5-(2-Fluoro-4-pentylaminomethyl-phenoxy)-pyrazine-2-carboxamide	Example 746, page 480, last two lines through page 481, line 12
3-Chloro-4-{4-[(3,3-dimethyl-butylamino)-methyl]-phenoxy}-benzamide	Example 704, page 440, lines 8-10
6-(4-[(2-(Tetrahydro-pyran-4-yl)-ethylamino)-methyl]-phenoxy)-nicotinamide	Page 41, lines 8-9
6-{4-[2-(3,3-Dimethyl-butylamino)-ethyl]-2,6-difluoro-phenoxy}-nicotinamide	Example 666, page 415, lines 16 through the end of page
6-{2-Chloro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide	Example 229, page 138, lines 8 through the end of page
3,5-Difluoro-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide	Example 694, page 430, last 2 lines through page 432, line 9
6-{2,3,6-Trifluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide	Example 714, page 449, line 1 through page 450, line 10
6-{2,6-Difluoro-4-[(3-methyl-butylamino)-methyl]-phenoxy}-nicotinamide	Example 713, page 448, line 17 through the end of page
3-Fluoro-4-{4-[(3-methyl-butylamino)-methyl]-phenoxy}-benzamide	Example 691, page 429, lines 10-20

Applicants have amended Claims 18-24, 26, 40 and 41 in view of cancelled claims and for clarity and consistency of presentation. It is respectfully contended no new matter has been added by any of the amendments.

Applicants request favorable consideration of this application and the presently claimed invention.

Respectfully submitted,

/John C. Demeter/

John C. Demeter  
Attorney for Applicants  
Registration No. 30,167  
Phone: 317-276-3785

Eli Lilly and Company  
Patent Division/FOG  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

October 18, 2007